newsfilter
← Latest News
GlobeNewswire·

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's diseaseLecanemab presentations